NABRIVA THERAPEUTICS PLC's ticker is and the CUSIP is G63637105. A total of 3 filers reported holding NABRIVA THERAPEUTICS PLC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $1,066,000 | -59.6% | 2,000 | 0.0% | 0.00% | – |
| Q4 2019 | $2,640,000 | +2934.5% | 2,000 | -94.4% | 0.00% | -100.0% |
| Q1 2019 | $87,000 | -40.4% | 35,500 | -64.5% | 0.02% | -47.1% |
| Q4 2018 | $146,000 | -67.0% | 100,000 | -52.9% | 0.03% | -61.8% |
| Q3 2018 | $443,000 | +677.2% | 212,500 | +1195.7% | 0.09% | +709.1% |
| Q2 2018 | $57,000 | -5.0% | 16,400 | +38.1% | 0.01% | -8.3% |
| Q1 2018 | $60,000 | -34.8% | 11,875 | -22.6% | 0.01% | -29.4% |
| Q4 2017 | $92,000 | – | 15,348 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 191,028 | $462,000 | 0.08% |
| Sterling Investment Advisors, Ltd. | 5,000 | $12,000 | 0.00% |
| IFP Advisors, Inc | 0 | $0 | 0.00% |